MX2024009773A - Composicion farmaceutica que comprende derivados de difenildiazol y metodos de uso. - Google Patents
Composicion farmaceutica que comprende derivados de difenildiazol y metodos de uso.Info
- Publication number
- MX2024009773A MX2024009773A MX2024009773A MX2024009773A MX2024009773A MX 2024009773 A MX2024009773 A MX 2024009773A MX 2024009773 A MX2024009773 A MX 2024009773A MX 2024009773 A MX2024009773 A MX 2024009773A MX 2024009773 A MX2024009773 A MX 2024009773A
- Authority
- MX
- Mexico
- Prior art keywords
- diphenyldiazole
- methods
- derivatives
- pharmaceutical composition
- composition including
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22159408 | 2022-03-01 | ||
| PCT/EP2023/055160 WO2023166045A1 (en) | 2022-03-01 | 2023-03-01 | Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009773A true MX2024009773A (es) | 2024-08-19 |
Family
ID=80623476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009773A MX2024009773A (es) | 2022-03-01 | 2023-03-01 | Composicion farmaceutica que comprende derivados de difenildiazol y metodos de uso. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250161273A1 (https=) |
| EP (1) | EP4486340A1 (https=) |
| JP (1) | JP2025508912A (https=) |
| KR (1) | KR20240155237A (https=) |
| CN (1) | CN118715010A (https=) |
| AU (1) | AU2023227368A1 (https=) |
| CA (1) | CA3246018A1 (https=) |
| CL (1) | CL2024002379A1 (https=) |
| IL (1) | IL314952A (https=) |
| MX (1) | MX2024009773A (https=) |
| PE (1) | PE20250781A1 (https=) |
| WO (1) | WO2023166045A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025068949A1 (en) | 2023-09-26 | 2025-04-03 | Teva Pharmaceutical Industries Ltd. | Emrusolmin for use in treating multiple system atrophy |
| KR20250090047A (ko) * | 2023-12-12 | 2025-06-19 | 가천대학교 산학협력단 | 긴 탄소사슬을 포함하는 리파펜틴, 암포테리신 b, 세틸피리디늄, 도미펜, 토코페르솔란을 유효성분으로 포함하는 시누클레인병증 치료용 약제학적 조성물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2687513B1 (en) * | 2008-06-09 | 2020-12-02 | Ludwig-Maximilians-Universität München | Drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases |
| KR102671166B1 (ko) * | 2015-12-14 | 2024-05-31 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | 3,5-디페닐-디아졸 화합물의 수용성 유도체 |
-
2023
- 2023-03-01 US US18/840,374 patent/US20250161273A1/en active Pending
- 2023-03-01 PE PE2024001775A patent/PE20250781A1/es unknown
- 2023-03-01 WO PCT/EP2023/055160 patent/WO2023166045A1/en not_active Ceased
- 2023-03-01 KR KR1020247029979A patent/KR20240155237A/ko active Pending
- 2023-03-01 JP JP2024550866A patent/JP2025508912A/ja active Pending
- 2023-03-01 CN CN202380024479.XA patent/CN118715010A/zh active Pending
- 2023-03-01 EP EP23707119.6A patent/EP4486340A1/en active Pending
- 2023-03-01 CA CA3246018A patent/CA3246018A1/en active Pending
- 2023-03-01 MX MX2024009773A patent/MX2024009773A/es unknown
- 2023-03-01 AU AU2023227368A patent/AU2023227368A1/en active Pending
- 2023-03-01 IL IL314952A patent/IL314952A/en unknown
-
2024
- 2024-08-08 CL CL2024002379A patent/CL2024002379A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250161273A1 (en) | 2025-05-22 |
| CL2024002379A1 (es) | 2025-01-24 |
| WO2023166045A1 (en) | 2023-09-07 |
| KR20240155237A (ko) | 2024-10-28 |
| EP4486340A1 (en) | 2025-01-08 |
| IL314952A (en) | 2024-10-01 |
| CA3246018A1 (en) | 2023-09-07 |
| AU2023227368A1 (en) | 2024-07-18 |
| JP2025508912A (ja) | 2025-04-10 |
| CN118715010A (zh) | 2024-09-27 |
| PE20250781A1 (es) | 2025-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023020442A2 (pt) | Inibidor da protease 1 específica de ubiquitina (usp1) | |
| AR122351A1 (es) | Derivados de metilquinazolinona como inhibidores de braf | |
| ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
| CL2023000921A1 (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead | |
| ECSP045004A (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes | |
| CY1115289T1 (el) | Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη | |
| EA200802390A1 (ru) | Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их | |
| AR047070A1 (es) | Derivados de difenilazetidona | |
| BRPI0617165A2 (pt) | Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos | |
| BRPI0418251C1 (pt) | fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo | |
| MX2024014861A (es) | Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo | |
| BRPI0819328A8 (pt) | Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos | |
| AR047928A1 (es) | Derivados de tetrahidropiridoindol | |
| MX2022001789A (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo. | |
| UY28691A1 (es) | Derivados de difenilazetidona | |
| ECSP088246A (es) | Nuevos derivados de benzotiazolona | |
| BR0315580A (pt) | Derivados de metileno uréia | |
| UY29087A1 (es) | Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico | |
| MX2024013019A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| UY29420A1 (es) | Derivados de 2-piridona,composiciones que los contienen, procesos de preparación y aplicación | |
| SA522431498B1 (ar) | مشتقات 3، 6-داي أمينو-بيريدازين-3-يل، تركيبات صيدلية تحتوي عليها واستخدامها في صورة عوامل مساعدة على تلاشي الخلايا | |
| CL2024002379A1 (es) | Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| UY29234A1 (es) | Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones. | |
| BR112018015629A2 (pt) | ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla? |